A research team from the University of Cambridge in the UK recently announced that a new DNA vaccine designed using artificial intelligence (AI) has completed its first human trial. It aims to provide broad-spectrum protection against all known human coronavirus variants and related viruses potentially transmitted from bats to humans through a single vaccination.
The vaccine is described by researchers as a "fundamentally new" type of vaccine, with key antigenic components designed entirely with AI. Traditional vaccines usually target a specific virus and train the immune system to recognize one or a few viral proteins. However, viruses continue to mutate. When the mutation range is large enough, the protective power of the original vaccine will be significantly reduced. This is why the influenza vaccine needs to be updated every year and the formula of the new coronavirus vaccine has been updated many times since 2021. The research team pointed out that AI provides a new solution to this problem: by analyzing the genetic data of thousands of related viruses, AI can screen out sequence fragments that are highly conserved among different strains and are not prone to changes during evolution, thus providing a target for vaccine design targeting the "entire virus family" instead of being limited to a certain known strain.
Specifically, the Cambridge team used AI to scan the "sarbecovirus" subgenus, including the viruses that cause SARS and COVID-19, as well as a series of animal coronaviruses, looking for common features that have been almost unchanged during long-term evolution. These stable regions were eventually used as immune targets for new vaccines. Researchers hope that by locking in these "common weaknesses" that are not prone to mutation, they can still maintain a certain degree of cross-protection when new related viruses emerge in the future, thereby buying valuable time to respond to unknown epidemics.
Different from the mRNA COVID-19 vaccine that the public is more familiar with, this new vaccine uses DNA technology. Compared with mRNA vaccines, DNA vaccines are generally more stable in storage and transportation and require lower cold chain conditions, which is particularly critical for low-income countries with limited cold chain infrastructure. In addition, the vaccine does not require traditional needle injection. Instead, the vaccine is injected into the skin through high-pressure fluid flow. This needle-free delivery method is expected to reduce the pain during vaccination, while making it easier to deploy quickly and improve vaccination efficiency in large-scale outbreaks.
From a public health perspective, researchers emphasize that if this technical approach proves effective, broad-spectrum vaccines are expected to change the way humans respond to emerging infectious diseases. By designing to target characteristics shared across strains within a virus family, broad-spectrum vaccines are expected to provide basic protection against new, yet-to-be-seen viruses early in an epidemic, allowing public health authorities to interrupt chains of transmission before a pandemic develops. The same idea is also regarded as a potential "game changer" in the field of influenza: currently, scientists need to predict in advance the dominant strains of each influenza season. Once the prediction is wrong, the protective effect of the vaccine will be greatly reduced. If a "universal influenza vaccine" can be developed that targets the shared characteristics of multiple influenza strains, this annual "catch-up war" is expected to end.
The latest Ebola epidemic highlights the practical urgency of this direction. Recent outbreaks in the Democratic Republic of Congo and Uganda have been driven primarily by the Bundibugyo strain, which can circumvent protection from existing vaccines, putting local communities at higher risk. While researchers are urgently developing a new vaccine against this specific strain, a broad-spectrum vaccine against the entire virus family, if deployed in advance, will likely avoid a similar passive situation of "strain replacement - vaccine lagging behind".
In this latest human trial, researchers report that it is the first AI-designed vaccine in the world to be tested in humans. The results showed that the DNA vaccine was able to stimulate the subjects' immune systems and produce antibodies that could recognize multiple sarbecoviruses. The trial also showed that this technical route was generally safe and well tolerated among the subjects. The team believes that this result shows that AI has important potential in designing new vaccines with "mutation resistance" against potential future pandemic pathogens, and that the needle-free drug delivery system brings additional advantages to the promotion of vaccination on a global scale.
However, researchers also admit that this progress is still far from a truly "universal vaccine." Although the immune response observed in the current study is broad-spectrum, the overall level is still moderate. It is still unclear how long the protective effect can be maintained and whether additional booster shots are needed. In addition, larger clinical trials are needed to verify whether the vaccine can indeed prevent or mitigate different viral infections under real-world conditions.
Experts point out that a universal vaccine that can be widely used will be difficult to fully mature within several years. Any new vaccine must still go through multi-stage, large-sample clinical trials to prove its safety, effectiveness and long-term protection capabilities. Nonetheless, this study shows that with the help of AI, the scientific community is gradually getting closer to this goal, and the systematic analysis and rapid design of large virus lineages with the help of algorithms may significantly shorten the time from concept to clinical application of next-generation vaccines.